Silver Book Fact

Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.

Harris S, Watts N, Genant H, et al. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: a Randomized Controlled Trial. JAMA. 1999; 282(14): 1344-52. http://jama.ama-assn.org/cgi/content/abstract/282/14/1344

Reference

Title
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: a Randomized Controlled Trial
Publication
JAMA
Publication Date
1999
Authors
Harris S, Watts N, Genant H, et al
Volume & Issue
Volume 282, Issue 14
Pages
1344-52
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.